Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Dr. Finn on Results of RESOURCE Study in Liver Cancer

January 31st 2017

Richard Finn, MD, associate professor of Medicine at the UCLA David Geffen School of Medicine, discusses results of the RESOURCE study in advanced liver cancer.

Dr. Finn on Studies of Pembrolizumab for Hepatocellular Carcinoma

January 31st 2017

Richard Finn, MD, associate professor of Medicine at the UCLA David Geffen School of Medicine, discusses studies of pembrolizumab (Keytruda) in patients with previously untreated hepatocellular carcinoma (HCC).

Dr. Al-Batran on Paclitaxel Plus Everolimus in Gastric Cancer

January 30th 2017

Salah-Eddin Al-Batran, MD, medical oncologist and director at the Institute of Clinical Cancer Research — Frankfurt, Germany, discusses the results of trial combining everolimus (Afinitor) with paclitaxel in the treatment of patients with gastric cancer.

Dr. Marshall on Molecular Variances Between Right- Versus Left-Sided Colon Cancer

January 30th 2017

John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital, associate director, Clinical Research, Lombardi Comprehensive Cancer Center at Georgetown University Hospital, discusses molecular variances between right- and left-sided colon cancer.

Dr. Lin on Advances in Radiation Therapy for Esophageal Cancer

January 28th 2017

Steven H. Lin, MD, PhD, associate professor, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, discusses advances in radiation therapy for patients with esophageal cancer.

Dr. Sears on Microbiota in Colon Cancer

January 28th 2017

Cynthia L. Sears, MD, professor of Medicine, at John Hopkins University School of Medicine, member of the Bloomberg-Kimmel Institute for Cancer Immunotherapy, discusses microbiota in patients with colon cancer.

Dr. Talamonti on Challenges Facing Minimally Invasive Surgery for Pancreatic Cancer

January 27th 2017

Mark S. Talamonti, MD, clinical professor, NorthShore University HealthSystem, discusses some of the challenges facing minimally invasive surgery for patients with pancreatic cancer.

Dr. O'Reilly on Tarextumab Combinations for Metastatic Pancreatic Cancer

January 27th 2017

Eileen O’Reilly, MD, associate director for clinical research at Memorial Sloan Kettering Cancer Center, discusses tarextumab combinations for patients with pancreatic cancer.

Lenvatinib Succeeds in Phase III Frontline HCC Trial

January 26th 2017

Frontline treatment with lenvatinib was shown to be noninferior to standard therapy with sorafenib in patients with unresectable hepatocellular carcinoma.

Dr. Chiorean on Combination Therapies for Pancreatic Cancer

January 26th 2017

Gabriela Chiorean, MD, associate professor of Medicine at the University of Washington, discusses adverse events of the phase I study of combination therapies for patients with pancreatic cancer.

Dr. Philip on Drug Developments for Pancreatic Cancer

January 25th 2017

Philip A. Philip, MD, PhD, FRCP, professor of Medicine at Wayne State University School of Medicine, clinical professor of Oncology at Barbara Ann Karmanos Cancer Institute, discusses drug developments for patients with pancreatic cancer.

Dr. Strosberg on Quality of Life for Midgut Neuroendocrine Tumors

January 25th 2017

Jonathan Strosberg, MD, medical oncologist, Department of Gastrointestinal Oncology, section head, Neuroendocrine Division, chair, Gastrointestinal Department Research Program, Moffitt Cancer Center, discusses quality of life in patients with midgut neuroendocrine tumors (NETs).

Dr. Talamonti on Surgical Advancements in Pancreatic Cancer

January 25th 2017

Mark S. Talamonti, MD, clinical professor, NorthShore University HealthSystem, discusses some of the recent surgical advancements in pancreatic cancer.

Dr. Mariette on a Study of Postoperative Mortality After Esophageal and Gastric Cancer Surgery

January 25th 2017

Christophe Mariette, MD, PhD, surgical oncologist, professor of Surgery, University Hospital of Lille, discusses the results of a study investigating postoperative mortality after patients undergo surgery for esophageal and gastric cancer.

Vemurafenib Adds to PFS in BRAF-mutant mCRC

January 25th 2017

Adding vemurafenib to the routinely employed combination of irinotecan and cetuximab prolonged progression-free survival in patients with BRAF-mutant metastatic colorectal cancer.

Dr. Loaiza-Bonilla on Right- Versus Left-Sided Colorectal Cancer

January 24th 2017

Arturo Loaiza-Bonilla, MD, medical oncologist, specialized in gastrointestinal malignancies, assistant professor of Clinical Medicine at the University of Pennsylvania, discusses findings of patients with right- versus left-sided tumors of colorectal cancer (CRC).

Nivolumab Activity Affirmed in Microsatellite Instability-High mCRC

January 24th 2017

The promising antitumor activity of nivolumab in patients with microsatellite instability-high metastatic colorectal cancer was sustained in an update of the phase II CheckMate-142 trial.

Dr. Strosberg on Future of 177Lu-Dotatate Therapy in Neuroendocrine Tumors

January 24th 2017

Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, discusses the future of using 177Lu-dotatate therapy to treat patients with neuroendocrine tumors.

Dr. Terashima on Bursectomy for Subserosal and Serosal Gastric Cancer

January 24th 2017

Masanori Terashima, MD, PhD, FACS, chairman of the Japanese Clinical Oncology Group, discusses bursectomy for patients with subserosal and serosal gastric cancer.

Trend Toward Better PFS With Four-Drug CRC Regimen

January 24th 2017

Patients with advanced colorectal cancer had a modest gain in progression-free survival with the addition of irinotecan to standard chemotherapy plus an angiogenesis inhibitor as induction therapy, a randomized trial showed.